East Kent Hospitals University NHS Foundation Trust Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2007
NCT00371059
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

East Kent Hospitals University NHS Foundation Trust

Active Ingredients

Drugs in Phase 4 Trials (1)

memantine (namenda) (1 trial)

Drugs in Phase 3 Trials (5)

acetylsalicylic acid (aspirin) (1 trial)

apixaban (eliquis) (1 trial)

dabigatran (pradaxa) (1 trial)

edoxaban (savaysa) (1 trial)

rivaroxaban (xarelto) (1 trial)

Drugs in Other Trials (1)

european elderberry (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 3)

Cardiovascular Diseases (Phase 3)

Cerebral Hemorrhage (Phase 3)

Dementia (Phase 4)

Hemorrhage (Phase 3)

Kidney Diseases (Phase 3)

Psychomotor Agitation (Phase 4)

Renal Insufficiency, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 7